SCHEMBL3007969

SCHEMBL3007969

Cc1cccc(C)c1Cc1csc(N2CCC(S(=O)(=O)c3ccc(F)c(Cl)c3)CC2)n1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.36
LMNA P02545 2/20 0.36
MEN1 O00255 2/20 0.36
ALDH1A1 P00352 2/20 0.36
KMT2A Q03164 2/20 0.36
POLB P06746 1/20 0.36
GAA P10253 1/20 0.36
TSHR P16473 1/20 0.36
HTT P42858 1/20 0.36
PKM P14618 1/20 0.35
PKLR P30613 1/20 0.35
DRD2 P14416 1/20 0.35
HTR2A P28223 1/20 0.35
HTR2C P28335 1/20 0.35
KCNH2 Q12809 1/20 0.35
USP2 O75604 1/20 0.35
RECQL P46063 1/20 0.35
HSD17B10 Q99714 1/20 0.35
RAB9A P51151 3/20 0.34
SMN1; SMN2 Q16637 3/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3012839 0.93 DNM1L (0.35) MAPTMEN1ALDH1A1KMT2APOLB
SCHEMBL3009827 0.92 LMNA (0.36) MAPTLMNAMEN1ALDH1A1KMT2A
SCHEMBL2998218 0.91 DRD2 (0.37) MAPTLMNAMEN1ALDH1A1KMT2A
SCHEMBL3001160 0.90 DRD2 (0.38) MAPTLMNAMEN1ALDH1A1KMT2A
SCHEMBL3001213 0.89 RAB9A (0.40) MAPTPOLBHTR2AHTR2CRAB9A
SCHEMBL3023007 0.89 MEN1 (0.38) MAPTLMNAMEN1KMT2ATSHR
SCHEMBL2999235 0.89 RAB9A (0.37) MAPTLMNAMEN1KMT2AHTR2A
SCHEMBL3012253 0.88 SCN8A (0.36) MAPTPKMPKLRDRD2HTR2A
SCHEMBL3023017 0.87 ALDH1A1 (0.43) MAPTLMNAALDH1A1DRD2HTR2A
SCHEMBL3007172 0.87 MAPT (0.41) MAPTLMNAMEN1ALDH1A1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA MAPT 18/4885LMNA 80/4885MEN1 454/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.